Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes
- PMID: 21593294
- PMCID: PMC3120182
- DOI: 10.2337/dc10-2415
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes
Abstract
Objective: Overweight and obese individuals are encouraged to lose 5-10% of their body weight to improve cardiovascular disease (CVD) risk, but data supporting this recommendation are limited, particularly for individuals with type 2 diabetes.
Research design and methods: We conducted an observational analysis of participants in the Look AHEAD (Action For Health in Diabetes) study (n=5,145, 40.5% male, 37% from ethnic/racial minorities) and examined the association between the magnitude of weight loss and changes in CVD risk factors at 1 year and the odds of meeting predefined criteria for clinically significant improvements in risk factors in individuals with type 2 diabetes.
Results: The magnitude of weight loss at 1 year was strongly (P<0.0001) associated with improvements in glycemia, blood pressure, triglycerides, and HDL cholesterol but not with LDL cholesterol (P=0.79). Compared with weight-stable participants, those who lost 5 to <10% ([means±SD] 7.25±2.1 kg) of their body weight had increased odds of achieving a 0.5% point reduction in HbA1c (odds ratio 3.52 [95% CI 2.81-4.40]), a 5-mmHg decrease in diastolic blood pressure (1.48 [1.20-1.82]), a 5-mmHg decrease in systolic blood pressure (1.56 [1.27-1.91]), a 5 mg/dL increase in HDL cholesterol (1.69 [1.37-2.07]), and a 40 mg/dL decrease in triglycerides (2.20 [1.71-2.83]). The odds of clinically significant improvements in most risk factors were even greater in those who lost 10-15% of their body weight.
Conclusions: Modest weight losses of 5 to <10% were associated with significant improvements in CVD risk factors at 1 year, but larger weight losses had greater benefits.
Trial registration: ClinicalTrials.gov NCT00017953.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3120182/bin/1481fig1.gif)
Similar articles
-
Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Jul. Report No.: 15-05222-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Jul. Report No.: 15-05222-EF-1. PMID: 29364620 Free Books & Documents. Review.
-
Effects of visceral adipose tissue reduction on CVD risk factors independent of weight loss: The Look AHEAD study.Endocr Res. 2017 May;42(2):86-95. doi: 10.1080/07435800.2016.1194856. Epub 2016 Jun 28. Endocr Res. 2017. PMID: 27351077 Free PMC article. Clinical Trial.
-
Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial.Diabetes Care. 2016 Aug;39(8):1345-55. doi: 10.2337/dc16-0509. Epub 2016 Jun 6. Diabetes Care. 2016. PMID: 27271190 Free PMC article. Clinical Trial.
-
Exercise and diet, independent of weight loss, improve cardiometabolic risk profile in overweight and obese individuals.Phys Sportsmed. 2011 May;39(2):87-97. doi: 10.3810/psm.2011.05.1898. Phys Sportsmed. 2011. PMID: 21673488 Review.
-
Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.Arch Intern Med. 2010 Sep 27;170(17):1566-75. doi: 10.1001/archinternmed.2010.334. Arch Intern Med. 2010. PMID: 20876408 Free PMC article. Clinical Trial.
Cited by
-
Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial.Lancet Reg Health Eur. 2024 Feb 9;39:100853. doi: 10.1016/j.lanepe.2024.100853. eCollection 2024 Apr. Lancet Reg Health Eur. 2024. PMID: 38803628 Free PMC article.
-
A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity.J Obes. 2024 May 10;2024:8056440. doi: 10.1155/2024/8056440. eCollection 2024. J Obes. 2024. PMID: 38765635 Free PMC article. Review.
-
Drug release profile of a novel exenatide long-term drug delivery system (OKV-119) administered to cats.BMC Vet Res. 2024 May 18;20(1):211. doi: 10.1186/s12917-024-04051-6. BMC Vet Res. 2024. PMID: 38762728 Free PMC article.
-
The role of low glycemic index and load diets in medical nutrition therapy for type 2 diabetes: an update.Hormones (Athens). 2024 May 16. doi: 10.1007/s42000-024-00566-7. Online ahead of print. Hormones (Athens). 2024. PMID: 38750304 Review.
-
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.Nat Med. 2024 May 13. doi: 10.1038/s41591-024-02996-7. Online ahead of print. Nat Med. 2024. PMID: 38740993
References
-
- Institute of Medicine Weighing the Options. Criteria for Evaluating Weight-Management Programs. Thomas PR, Ed. Washington, DC, National Academy Press, 1995, p. 282 - PubMed
-
- Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397–415 - PubMed
-
- Vidal J. Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord 2002;26(Suppl. 4):S25–S28 - PubMed
-
- Van Gaal LF, Mertens IL, Ballaux D. What is the relationship between risk factor reduction and degree of weight loss? Eur Heart J Suppl 2005;7:L21–L26
-
- Kris-Etherton PM, Krummel D, Russell ME, et al. The effect of diet on plasma lipids, lipoproteins, and coronary heart disease. J Am Diet Assoc 1988;88:1373–1400 - PubMed